Table 2.
Prostein and tumor phenotype
| Prostein immunostaining result | |||||||
|---|---|---|---|---|---|---|---|
| n | negative (%) | weak (%) | moderate (%) | strong (%) | P | ||
| Invasive breast carcinoma of no special type | pT1 | 774 | 95.9 | 3.5 | 0.6 | 0 | 0.2176 |
| pT2 | 626 | 94.9 | 4.3 | 0.8 | 0 | ||
| pT3-4 | 125 | 93.6 | 5.6 | 0 | 0.8 | ||
| G1 | 191 | 96.3 | 3.1 | 0.5 | 0 | 0.0105 | |
| G2 | 817 | 96.9 | 2.7 | 0.4 | 0 | ||
| G3 | 562 | 92.3 | 6.2 | 1.2 | 0.2 | ||
| pN0 | 698 | 95.3 | 4.4 | 0.3 | 0 | 0.1691 | |
| pN+ | 527 | 94.7 | 4.2 | 1 | 0.2 | ||
| pM0 | 198 | 96.5 | 3 | 0.5 | 0 | 0.5637 | |
| pM1 | 116 | 94.8 | 3.4 | 1.7 | 0 | ||
| HER2 negative | 889 | 96.4 | 3 | 0.6 | 0 | 0.0312 | |
| HER2 positive | 124 | 91.9 | 4.8 | 3.2 | 0 | ||
| ER negative | 215 | 92.1 | 6 | 1.9 | 0 | 0.033 | |
| ER positive | 746 | 96.5 | 2.8 | 0.7 | 0 | ||
| PR negative | 414 | 94.2 | 4.6 | 1.2 | 0 | 0.1836 | |
| PR positive | 594 | 96.6 | 2.7 | 0.7 | 0 | ||
| non-triple negative | 786 | 95.8 | 3.2 | 1 | 0 | 0.5848 | |
| triple negative | 144 | 94.4 | 4.9 | 0.7 | 0 | ||
| Adenocarcinoma of the pancreas | pT1 | 16 | 75 | 18.8 | 6.3 | 0 | 0.7582 |
| pT2 | 71 | 60.6 | 25.4 | 11.3 | 2.8 | ||
| pT3 | 384 | 60.9 | 29.7 | 7.3 | 2.1 | ||
| pT4 | 30 | 70 | 16.7 | 10 | 3.3 | ||
| G1 | 17 | 52.9 | 35.3 | 11.8 | 0 | 0.7482 | |
| G2 | 353 | 61.8 | 28 | 7.4 | 2.8 | ||
| G3 | 108 | 62 | 30.6 | 6.5 | 0.9 | ||
| pN0 | 108 | 58.3 | 24.1 | 14.8 | 2.8 | 0.0424 | |
| pN+ | 392 | 62.5 | 29.3 | 6.1 | 2 | ||
| R0 | 253 | 62.1 | 26.1 | 9.1 | 2.8 | 0.5101 | |
| R1 | 208 | 63 | 27.9 | 8.2 | 1 | ||
| MMR proficient | 453 | 61.8 | 28 | 7.7 | 2.4 | 0.8875 | |
| MMR deficient | 3 | 66.7 | 33.3 | 0 | 0 | ||
| Adenocarcinoma of the stomach | pT1-2 | 63 | 84.1 | 9.5 | 6.3 | 0 | 0.4894 |
| pT3 | 126 | 85.7 | 11.1 | 3.2 | 0 | ||
| pT4 | 126 | 84.9 | 13.5 | 1.6 | 0 | ||
| pN0 | 86 | 87.2 | 9.3 | 3.5 | 0 | 0.8345 | |
| pN+ | 223 | 86.1 | 10.8 | 3.2 | 0.0 | ||
| MMR proficient | 40 | 70 | 15 | 15 | 0 | 0.0015 | |
| MMR deficient | 259 | 85.7 | 12.7 | 1.5 | 0 | ||
| Adenocarcinoma of the colon | pT1 | 80 | 78.8 | 18.8 | 1.3 | 1.3 | 0.0061 |
| pT2 | 414 | 70.5 | 25.6 | 3.1 | 0.7 | ||
| pT3 | 1195 | 81.1 | 15.6 | 2.9 | 0.4 | ||
| pT4 | 416 | 79.1 | 17.8 | 2.4 | 0.7 | ||
| pN0 | 1101 | 77.7 | 17.9 | 3.7 | 0.6 | 0.0608 | |
| pN+ | 993 | 79.5 | 18.2 | 1.8 | 0.5 | ||
| V0 | 1514 | 77.8 | 18.1 | 3.4 | 0.7 | 0.0139 | |
| V1 | 546 | 81.3 | 17.2 | 1.3 | 0.2 | ||
| L0 | 684 | 80 | 15.8 | 3.7 | 0.6 | 0.1454 | |
| L1 | 1387 | 78.1 | 19 | 2.4 | 0.6 | ||
| right side | 452 | 75.4 | 19.5 | 3.8 | 1.3 | 0.0479 | |
| left side | 1187 | 80.5 | 16.7 | 2.4 | 0.4 | ||
| MMR proficient | 1104 | 79.3 | 17.7 | 2.4 | 0.6 | 0.5061 | |
| MMR deficient | 85 | 77.6 | 17.6 | 4.7 | 0 | ||
| RAS wildtype | 422 | 85.5 | 12.8 | 1.4 | 0.2 | 0.0133 | |
| RAS mutation | 328 | 77.4 | 17.7 | 4 | 0.9 | ||
| BRAF wildtype | 123 | 79.7 | 16.3 | 1.6 | 2.4 | 0.6308 | |
| BRAF V600E mutation | 16 | 75 | 12.5 | 6.3 | 6.3 | ||
Abbreviation: pT Pathological tumor stage, G Grade, pN Pathological lymph node status, pM Pathological status of distant metastasis, R Resection margin status, V Venous invasion, L Lymphatic invasion, PR Progesteron receptor, MMR Mismatch repair, ER Estrogen receptor